Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Nicholas C TurnerMafalda OliveiraSacha J HowellFlorence DalencJavier CortesHenry L Gomez MorenoXichun HuKomal JhaveriPetr KrivorotkoSibylle LoiblSerafin Morales MurilloMeena OkeraYeon Hee ParkJoo Hyuk SohnMasakazu ToiEriko TokunagaSamih YousefLyudmila ZhukovaElza C de BruinLynda GrinstedGaia SchiavonAndrew FoxleyHope S Rugonull nullPublished in: The New England journal of medicine (2023)
Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. (Funded by AstraZeneca and the National Cancer Institute; CAPItello-291 ClinicalTrials.gov number, NCT04305496.).